© 2023 Merck KGaA, Darmstadt, Germany and/or its affiliates. All rights reserved. EMD Serono, Inc. is the healthcare business of Merck KGaA, Darmstadt, Germany in the US and Canada.
EMD Serono is among key companies with a focus on pioneering research into the multiple pathways involved in DNA damage response (DDR). Inhibiting these pathways can help disrupt the tumor’s ability to repair damage and can restore sensitivity to treatments. Our active areas of research include:
- The inhibition of DNA-PK, ATR and ATM enzymes to prevent them from coordinating DNA repair, thereby irreparably driving cell death
TARGETS PATHWAYS UNDER INVESTIGATION
Abbreviations:
ATM, ataxia telangiectasia mutated; ATR, ataxia telangiectasia RAD3-related; DNA-PK, DNA-dependent protein kinase.
